Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) : vimarsana.com

Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) Both treatment arms with the combination of Miconazole (2%) and Domiphen Bromide (0.14% or 0.29%) demonstrated excellent safety and tolerability Low dose (0.14%) showed significant improvement over active control in clinical and mycological outcome at day 291 Liège, Belgium – 30 January 2024, 07:00 AM CET – Regulated information – Inside information – Hyloris Pha

Related Keywords

Belgium , Belgian , Miconazole Domiphen , Jean Luc Vandebroek , Stijn Van Rompay , Hyloris Pharmaceuticals , Purna Pharmaceuticals , Linkedin , Hyloris Pharmaceuticals Sa Euronext Brussels , Purna Female Healthcare Announce Positive Results , Acute Vulvovaginal Candidiasis , Domiphen Bromide , Euronext Brussels , Miconazole Domiphen Bromide , Van Rompay , Chief Executive Officer , Female Healthcare , Luc Vandebroek , Lancet Infectious Diseases , Clinical Infectious Diseases , Expert Opinion , Vulvovaginal Candidiasis , Omiphen Bromide , Linical Outcome , He Company , Iège , Elgium , Uronext Brussels , Urna , Harmaceuticals , Tijn Van Rompay , Fficacy ,